Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP0892 in adolescents with peanut allergy
NCT03755713Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP0892 in peanut allergy (3 arms), sponsored by Astellas Pharma. Primary endpoints: Treatment Emergent Adverse Events, Local Reactogenicity Reactions and 4 more. Started Mar 2019; status: completed.
02
Drugs
ASP0892
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03755713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755713.